Financial statements Syngene Biotech
Balance sheet of Syngene Biotech
Company age:
Age:
12 y. 8 m. 19 d.
Share capital:
Share capital:
5 000 PLN
Balance sheet data of SYNGENE BIOTECH
|
Year
|
2021
|
2022
|
2023
|
|---|---|---|---|
| Total assets | 132 399,16 | 102 909,16 | 96 319,16 |
| A. Fixed assets | 500,00 | 500,00 | 500,00 |
| B. Current assets | 131 899,16 | 102 409,16 | 95 819,16 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | - |
| D. Own shares (stocks) | 0,00 | 0,00 | - |
| Total liabilities | 132 399,16 | 102 909,16 | 96 319,16 |
| A. Equity | 131 868,66 | 102 355,66 | 95 888,66 |
| B. Liabilities and provisions for liabilities | 530,50 | 553,50 | 430,50 |
| I. Long-term liabilities | 0,00 | 0,00 | - |
| II. Short-term liabilities | 530,50 | 553,50 | 430,50 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.